Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL
Information source: Indiana University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Non Hodgkin's Lymphoma
Intervention: clofarabine (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Indiana University School of Medicine Official(s) and/or principal investigator(s): Sherif Farag, MD, PhD, Principal Investigator, Affiliation: Indiana University
Summary
This is a phase I trial to determine the maximum tolerated dose (MTD) of clofarabine in a
combination with high-dose etoposide and cyclophosphamide. This is an initial step in
developing a novel myeloablative preparative regimen for autologous hematopoietic stem cell
transplantation (ASCT). While this phase I trial will initially develop the regimen in
patients with refractory disease, it is expected that it will find its best application in
patients with less advanced disease.
Clinical Details
Official title: A Phase I Trial of Clofarabine in Combination With High-Dose Etoposide and Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation for Patients With High-Risk or Refractory Non-Hodgkin's Lymphoma
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Determine the maximum tolerated dose (MTD) of clofarabine in association with high-dose etoposide and cyclophosphamide followed by ASCT in patients with refractory lymphoma malignancies.
Secondary outcome: Assessment of the toxicity of the combination of clofarabine, and high-dose etoposide and cyclophosphamide-- Describe engraftment kinetics-- Describe the response rate-- Describe relapse rate and event-free survival-- Assess clofarabine p
Detailed description:
All patients will receive the same doses of etoposide and cyclophosphamide. The dose of
clofarabine will be escalated in successive cohorts of patients. Using a standard dose
escalation design, successive cohorts of 3 patients will be treated with escalating doses of
clofarabine (see Section 5. 5 below). At the MTD (or highest dose-level if the MTD is not
reached), the cohort will be expanded to 10 patients to better investigate correlative
studies and give some preliminary idea of efficacy.
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Documentation of disease. Patients must have one of the following disease types:
- Diffuse large cell non-Hodgkin's lymphoma, mediastinal B-cell lymphoma, or
peripheral T-cell lymphoma that is:
- Primary refractory (achievement less than complete response)
- Relapsed and refractory (achievement less than a partial response) to at
least a single salvage therapy
- Relapsed or primary refractory Follicular lymphoma (FL) with a high FL
International Prognostic Index.
- Large cell transformation of lymphoma from a more indolent lymphoma (e. g.,
follicular, marginal zone, etc.)
- Mantle cell lymphoma that is:
- Primary Refractory (achievement less than complete response)
- Relapsed (regardless of chemosensitivity of relapsed disease)
2. Patients who received prior autologous stem cell transplantation are not eligible.
3. Patient age 18-70 years
4. Performance status ECOG 0-1
5. Required baseline laboratory values:
- LVEF > 45% corrected
- DLCO > 50% of predicted value (corrected for hemoglobin)
- Serum creatinine ≤ 2. 0 mg/dl or estimated creatinine clearance of ≥60 ml/min
- Bilirubin < 1 x upper limit of normal value.
- AST and ALT < 1 x upper limit of normal value.
6. Signed written informed consent. Patient must be capable of understanding the
investigational nature of the investigational nature, potential risks and benefits of
the study, and able to provide valid informed consent
Exclusion Criteria:
1. No active infection. Patients with active infections requiring oral or intravenous
antibiotics are not eligible for enrollment until resolution of infection.
2. No HIV disease. Patients with immune dysfunction are at a significantly higher risk
of infection from intensive immunosuppressive therapies.
3. Non-pregnant and non-nursing. Treatment under this protocol would expose a fetus to
significant risks. Women of childbearing potential should have a negative pregnancy
test prior to study entry. Women and men of reproductive potential should agree to
use an appropriate method of birth control throughout their participation in this
study due to the teratogenic potential of the therapy utilized in this trial.
Appropriate methods of birth control include oral contraceptives, implantable
hormonal contraceptives (Norplant®), or double barrier method (diaphragm plus
condom).
Locations and Contacts
Indiana University Cancer Center, Indianapolis, Indiana 46202, United States
Additional Information
Indiana University Cancer Center 'Find a Clinical Trial'
Starting date: May 2007
Last updated: September 10, 2014
|